255 related articles for article (PubMed ID: 26190526)
21. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
22. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Pilotto S; Novello S; Peretti U; Kinspergher S; Ciuffreda L; Milella M; Carbognin L; Vavalà T; Ferrara R; Caccese M; Tortora G; Bria E
Expert Opin Investig Drugs; 2015; 24(9):1143-61. PubMed ID: 26065529
[TBL] [Abstract][Full Text] [Related]
23. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.
Aprile G; Bonotto M; Ongaro E; Pozzo C; Giuliani F
Drugs; 2013 Dec; 73(18):2003-15. PubMed ID: 24277700
[TBL] [Abstract][Full Text] [Related]
24. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
[TBL] [Abstract][Full Text] [Related]
25. Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.
Aalders KC; Tryfonidis K; Senkus E; Cardoso F
Cancer Treat Rev; 2017 Feb; 53():98-110. PubMed ID: 28088074
[TBL] [Abstract][Full Text] [Related]
26. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
27. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
[TBL] [Abstract][Full Text] [Related]
28. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.
de Marinis F; Bria E; Ciardiello F; Crinò L; Douillard JY; Griesinger F; Lambrechts D; Perol M; Ramalingam SS; Smit EF; Gridelli C
J Thorac Oncol; 2016 Jul; 11(7):1153-69. PubMed ID: 27063293
[TBL] [Abstract][Full Text] [Related]
29. Evolution of ramucirumab in the treatment of cancer - A review of literature.
Vennepureddy A; Singh P; Rastogi R; Atallah JP; Terjanian T
J Oncol Pharm Pract; 2017 Oct; 23(7):525-539. PubMed ID: 27306885
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
[TBL] [Abstract][Full Text] [Related]
31. [Angiogenesis and breast cancer].
Bachelot T; Ray-Coquard I; Cassier P; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S203-10. PubMed ID: 17846006
[TBL] [Abstract][Full Text] [Related]
32. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
33. Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors.
Sanchez-Gastaldo A; Gonzalez-Exposito R; Garcia-Carbonero R
Target Oncol; 2016 Aug; 11(4):479-87. PubMed ID: 26887374
[TBL] [Abstract][Full Text] [Related]
34. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
35. Targeting angiogenesis in the treatment of lung cancer.
Wheatley-Price P; Shepherd FA
J Thorac Oncol; 2008 Oct; 3(10):1173-84. PubMed ID: 18827616
[TBL] [Abstract][Full Text] [Related]
36. Targeting angiogenesis in advanced breast cancer.
Zelnak AB; O'Regan RM
BioDrugs; 2007; 21(4):209-14. PubMed ID: 17628118
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
38. Ramucirumab in the treatment of non-small cell lung cancer.
Arrieta O; Zatarain-Barrón ZL; Cardona AF; Carmona A; Lopez-Mejia M
Expert Opin Drug Saf; 2017 May; 16(5):637-644. PubMed ID: 28395526
[TBL] [Abstract][Full Text] [Related]
39. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.
Falcon BL; Chintharlapalli S; Uhlik MT; Pytowski B
Pharmacol Ther; 2016 Aug; 164():204-25. PubMed ID: 27288725
[TBL] [Abstract][Full Text] [Related]
40. VEGF as a potential target in lung cancer.
Frezzetti D; Gallo M; Maiello MR; D'Alessio A; Esposito C; Chicchinelli N; Normanno N; De Luca A
Expert Opin Ther Targets; 2017 Oct; 21(10):959-966. PubMed ID: 28831824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
